SNTI 10-Q: SEC filing

Senti Biosciences

Filed with the SEC on · accession 0001628280-26-074183

SNTI filed a 10-Q (quarterly report) with the SEC on Nov 16, 2026. The quarterly report: unaudited results for the quarter plus management’s comments.

Summary of the filing

Senti Biosciences filed its Q3 2026 Form 10-Q, reporting continued net losses and a going-concern uncertainty, alongside a July 2026 merger agreement and related contingent value rights, plus new senior secured convertible note financings.

Key details

FilerSenti Biosciences Holdings, Inc.
Convertible note lenderCeladon Partners SPV 24, LLC
Convertible note lenderNSG Bio Innovation Fund L.P.
Related party / lease counterpartyGeneFab

✦ Ask GOAX AI about this filing — what it means for SNTI, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for SNTI?

Click here

Frequently asked questions

What did SNTI file with the SEC on Nov 16, 2026?

SNTI filed a 10-Q (SEC filing). Senti Biosciences filed its Q3 2026 Form 10-Q, reporting continued net losses and a going-concern uncertainty, alongside a July 2026 merger agreement and related contingent value rights, plus new senior secured convertible note financings.

How do I read a 10-Q?

The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.

Other SNTI SEC filings

Get alerts when SNTI files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days